Glucose tetrasaccharide (Glc4) is used as a reference in analysis of urinary glucose tetrasacchaide, a biomarker for Pompe disease and other glycogen storage diseases.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Other Notes
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Pompe disease is an autosomal recessive disorder caused by deficiency of the lysosomal enzyme, acid alpha-glucosidase (GAA). To the best of our knowledge, no studies have reported the results of systematic and sequential CT analyses before and during ERT. In
Journal of immunological methods, 48(1), 109-119 (1982-01-01)
A radioimmunoassay is described that allows rapid determination of a urinary oligosaccharide -- Glc alpha 1-6Glc alpha 1-4Glc alpha 1-4Glc [(Glc)4] -- at concentrations greater than 2 pmol/microliter. Antibodies produced in rabbits immunized with the phenethylamine derivative of (Glc)4 coupled
Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.
Patients with glycogen storage disease type II (GSD II) typically excrete increased amounts of a glycogen-derived glucose tetrasaccharide, Glcalpha1-6Glcalpha1-4Glcalpha1-4Glc (Glc(4)), in the urine. With the advent of a new enzyme replacement therapy for GSD II, there is a need for
Journal of immunological methods, 68(1-2), 227-234 (1984-03-30)
Binding of a human urinary tetrasaccharide (Glc alpha 1-6Glc alpha 1-4Glc alpha 1-4Glc) by a mouse monoclonal antibody, 61.1, shows an unusually large dependence upon temperature. Association constants determined by equilibrium dialysis double for each 8 degrees C downward shift
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
